Introducing the Adcendo Leadership Team

Adcendo’s leadership team has a proven track record in ADC development, having played a direct role in the discovery, development and approval of multiple marketed ADC therapies, including Trodelvy®, Enhertu®, Tivdak®. With our deep expertise spanning preclinical and clinical development, regulatory strategy, CMC, and commercialization, our team combines cutting-edge biotech innovation with the operational excellence of leading global pharma.

Michael Pehl, MSc

Chief Executive Officer

Michael serves as our Chief Executive Officer and a Board Director. Michael brings ample leadership experience from global pharmaceutical and biotechnology companies, having led multiple marketed hematology & oncology products through development and commercialization, including Revlimid®, Vidaza®, Trodelvy®, Abraxane® and Reblozyl®. Among his many roles, Michael served as Chief Executive Officer of Immunomedics, Inc. and President of Hematology & Oncology of Celgene Corporation.

Lone H. Ottesen, MD, PHD

Chief Medical Officer

Lone serves as our Chief Medical Officer, bringing extensive expertise in global drug development across antibody-drug conjugates (ADCs), immune therapies and small molecules, from first-in-human studies to global registration-directed trials. Prior to joining Adcendo, Lone led several Global Clinical Development teams at AstraZeneca PLC, Early Oncology Development at Eisai Inc., and held key medical leadership roles at GlaxoSmithKline Oncology.

Fang Z. Ni, Pharm.D.

Chief Financial Officer

Fang Ni serves as our Chief Financial Officer and leads our operations in the United States. He brings a strong track record in executive leadership, corporate development, financial strategy and growth. Before joining Adcendo, Fang served as Chief Financial Officer and Chief Business Officer at Black Diamond Therapeutics. He also held the role of Chief Business Officer at Monte Rosa Therapeutics and drove strategic growth at several other innovative biotech startups. Fang previously worked as a Principal at Versant Ventures supporting biotech investments and held corporate development roles at Roche Pharmaceuticals across its U.S. and Swiss operations.

Dominik Mumberg, PhD

Chief Scientific Officer

Dominik serves as our Chief Scientific Officer, overseeing the company’s research and nonclinical development activities from target selection through pharmacology and IND-enabling studies. Prior to joining Adcendo, Dominik served in multiple leadership roles at Schering AG and Bayer AG, including VP of Oncology Research and Translational Innovation Lead. Under Dominik’s leadership, numerous programs advanced from research into clinical development, including ADCs, radio-immunoconjugates, and targeted therapies.

Pernille Hemmingsen, PhD

Chief Technology Officer

Pernille serves as our Chief Technology Officer and is responsible for CMC and global supply at Adcendo. Pernille brings over 20 years of technical operations experience in the pharmaceutical industry. Prior to joining Adcendo, Pernille served as VP of Global Product Development and Supply at Savara ApS, as well as led the Tivdak® CMC program from non-clinical through late-stage development at Genmab A/S.

James Wang, PhD

VP, Head of Business Development

James serves as our VP, Head of Business Development and is responsible for alliance management, competitive intelligence, and intellectual property at Adcendo. Prior to joining Adcendo, James served as Senior Director of Business Development at Innovent Biologics Inc, and Simcere Pharmaceuticals Group, leading numerous strategic licensing deals for assets and technologies, including ADCs. Earlier in his career, James served as Associate Director, Global Product & Portfolio Strategy at AstraZeneca PLC

Margaret McNaull, BSc, MBA

VP, Head of Clinical Operations

Margaret serves as our VP, Head of Clinical Operations, bringing global development expertise spanning ADCs, immune therapies, small molecules as well as biosimilars, spanning early development to post-commercialization. Prior to joining Adcendo, Margaret was head of Project Management Centre of Excellence at AstraZeneca PLC and led clinical operations across multiple late-stage development programs through regulatory submission and approval.

Victoria Marsh, PhD

VP, Head of Regulatory and Safety

Victoria (Vic) serves as our VP, Head of Regulatory and Safety, driving regulatory strategies and ensuring the safety and compliance of products across the Adcendo portfolio. Vic brings a proven track record of global regulatory leadership for a range of ADCs, biologics, and small molecule drugs spanning their full product lifecycle. Prior to joining Adcendo, Vic served as Executive Director at AVROBIO Inc, Senior Director at AstraZeneca PLC, and consultant to several biotech companies.

Mikkel Krogh-Madsen, PhD

VP, Head of Portfolio & Program Management

Mikkel serves as our VP, Head of Portfolio & Program Management, leading the project management organization and portfolio strategy at Adcendo. Prior to joining Adcendo, Mikkel served as Global Project Leader & Director at LEO Pharma A/S and was responsible for global R&D strategy across phases of clinical development for biologics products such as Kyntheum® and temtokibart. In addition, Mikkel also served on the Strategic Development Leadership Team at LEO Pharma

Christoffer Nielsen, PhD

VP Operations, General Manager & Co-founder

Christoffer (Chris) co-founded Adcendo ApS and serves as our VP Operations and General Manger, responsible for our day-to-day operations and associated functions. Christoffer brings more than 15 years of scientific and management experience, ranging from early discovery of our programs to operational management roles at Adcendo